Roghayeh Pour-Bagher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Roghayeh Pour-Bagher has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Ali Nosrati Andevari
Department of Clinical Biochemistry, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
1 shared publicationAshkan Garshasbi
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
1 shared publication- Durdi Qujeq
Department of Biochemistry, School of Medicine, Babol University of Medical Sciences, Babol, Iran
1 shared publication - Farzin Sadeghi
Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
1 shared publication Fatemeh Naghizadeh Nazarloo
Pasteur Institute of Iran, Tehran, Iran
1 shared publication- Gholamreza Asadikaram
Department of Clinical Biochemistry, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Protocol for a systematic review and meta-analysis: the effects of atorvastatin on interleukin-1β (IL-1β) levels in patients
Background: Atorvastatin is a lipophilic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor with potential pleiotropic anti-inflammatory effects. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine implicated in cardiovascular, metabolic, and autoimmune diseases. However, evidence regarding the effect of atorvastatin on IL-1β concentrations is inconsistent. Objective: To systematically evaluate the effect of atorvastatin on IL-1β concentrations in human participants. Methods: This protocol follows PRISMA-P guidelines. We will search PubMed, Scopus, Web of Science, and Embase for English-language, peer-reviewed studies published from January 2005 through October 2025. Eligible studies will include randomized controlled trials, controlled non-randomized studies, and uncontrolled longitudinal before-after studies of atorvastatin monotherapy that report IL-1β at baseline and follow-up, change scores, or comparable endline values in the intervention and comparator groups. We will synthesize results separately by study design and comparator structure. If appropriate after assessing clinical and methodological comparability, we will conduct cross-design synthesis only as an exploratory analysis. Mean differences (MD) or standardized mean differences (SMD) will be pooled using random-effects models. We will assess heterogeneity using I 2 and evaluate the certainty of the evidence using GRADE. Outcomes: We will estimate whether atorvastatin changes IL-1β concentrations and explore whether the dose, treatment duration, clinical condition, study design, and assay method modify the estimated effect. Ethics and dissemination: Ethical approval is not required because we will use only publiclyavailable data. We will submit findings to a peer-reviewed journaland present them at scientific meetings.
- 10 November 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
Open AccessProtocol for a systematic review and meta-analysis: the effects of atorvastatin on interleukin-1β (IL-1β) levels in patients
Background: Atorvastatin is a lipophilic 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor with potential pleiotropic anti-inflammatory effects. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine implicated in cardiovascular, metabolic, and autoimmune diseases. However, evidence regarding the effect of atorvastatin on IL-1β concentrations is inconsistent. Objective: To systematically evaluate the effect of atorvastatin on IL-1β concentrations in human participants. Methods: This protocol follows PRISMA-P guidelines. We will search PubMed, Scopus, Web of Science, and Embase for English-language, peer-reviewed studies published from January 2005 through October 2025. Eligible studies will include randomized controlled trials, controlled non-randomized studies, and uncontrolled longitudinal before-after studies of atorvastatin monotherapy that report IL-1β at baseline and follow-up, change scores, or comparable endline values in the intervention and comparator groups. We will synthesize results separately by study design and comparator structure. If appropriate after assessing clinical and methodological comparability, we will conduct cross-design synthesis only as an exploratory analysis. Mean differences (MD) or standardized mean differences (SMD) will be pooled using random-effects models. We will assess heterogeneity using I 2 and evaluate the certainty of the evidence using GRADE. Outcomes: We will estimate whether atorvastatin changes IL-1β concentrations and explore whether the dose, treatment duration, clinical condition, study design, and assay method modify the estimated effect. Ethics and dissemination: Ethical approval is not required because we will use only publiclyavailable data. We will submit findings to a peer-reviewed journaland present them at scientific meetings.
- Open Access
Expression Status of Rap1 Pathway-Related Genes in Liver Metastases Compared with Corresponding Primary Colorectal Cancer
Understanding molecular networks of CRLM is an ongoing area of research. In this study, paired CRC tissue and adjacent noncancerous tissue from 15 non-metastatic CRC patients and paired CRC tissue and matched liver metastatic tissues from 15 CRLM patients along with their adjacent noncancerous tissues were evaluated. We assessed Rap1 pathway-related genes including NRAS, FGF-1, NGF, and KDR expression by qRT-PCR and their protein status by Western blot. In CRLM patients, NRAS, FGF1, and KDR mRNA and protein were expressed at higher levels in metastatic than in CRC primary tumor and adjacent noncancerous tissue (p < 0.05). In non-metastatic patients, NRAS, FGF1, KDR, and NGF gene expression did not differ between CRC primary tumor-and adjacent noncancerous tissue (p > 0.05). ROC curve analysis showed a reasonable diagnostic accuracy of NRAS, FGF1, KDR, and FGF for the discrimination of metastatic patients from non- metastatic ones on analysis of their primary tumors. The data suggest that further functional studies on Rap1-related genes’ role in CRLM are needed. In conclusion, the present data broaden our knowledge about specific molecular characteristics of CRLM. An increased understanding of the molecular features of metastasis has the potential to create more successful treatment, or prevention, of metastasis, especially in multimodal primary tumor treatment.
Open AccessExpression Status of Rap1 Pathway-Related Genes in Liver Metastases Compared with Corresponding Primary Colorectal Cancer
Understanding molecular networks of CRLM is an ongoing area of research. In this study, paired CRC tissue and adjacent noncancerous tissue from 15 non-metastatic CRC patients and paired CRC tissue and matched liver metastatic tissues from 15 CRLM patients along with their adjacent noncancerous tissues were evaluated. We assessed Rap1 pathway-related genes including NRAS, FGF-1, NGF, and KDR expression by qRT-PCR and their protein status by Western blot. In CRLM patients, NRAS, FGF1, and KDR mRNA and protein were expressed at higher levels in metastatic than in CRC primary tumor and adjacent noncancerous tissue (p < 0.05). In non-metastatic patients, NRAS, FGF1, KDR, and NGF gene expression did not differ between CRC primary tumor-and adjacent noncancerous tissue (p > 0.05). ROC curve analysis showed a reasonable diagnostic accuracy of NRAS, FGF1, KDR, and FGF for the discrimination of metastatic patients from non- metastatic ones on analysis of their primary tumors. The data suggest that further functional studies on Rap1-related genes’ role in CRLM are needed. In conclusion, the present data broaden our knowledge about specific molecular characteristics of CRLM. An increased understanding of the molecular features of metastasis has the potential to create more successful treatment, or prevention, of metastasis, especially in multimodal primary tumor treatment.